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Background and Objectives Apheresis platelet concentrates sometimes contain
persistent aggregates (PA). Because apheresis involves extracorporeal circulation,
we hypothesized that interactions between GPIba and von Willebrand factor
(VWF) underlie their origin.
Materials and Methods Platelets in donations with PA were compared to aggre-
gate-free (AF) controls. Flow cytometry was used to determine platelet bound
VWF. Degranulation was measured using P-selectin expression in flow cytometry
and cytokine release using immunosorbent assays. Platelet adhesion to VWF was
assessed in hydrodynamic flow and real-time video microscopy.
Results Platelets in PA concentrates had significantly more (P = 0009, n ≥ 8)
bound VWF compared to AF platelets, but differences in VWF concentration,
VWF collagen binding, activated VWF or GPIba expression were not found.
Degranulation was higher (P = 0030, n = 7) in PA than AF concentrates on day
1 of storage, but adhesion to immobilized VWF under hydrodynamic flow condi-
tions was normal at that moment. On day 6, however, significantly less VWF
adhesion (P = 0009, n ≥ 6) was found for PA platelets compared to AF, indicat-
ing accelerated storage lesion in PA products. In a model that mimicks PA for-
mation by chemically induced binding of VWF to platelets, we found that
degranulation, phosphatidylserine expression and metabolism did not differ with
paired controls at any time during subsequent storage.
Conclusion Accelerated storage lesion is found in concentrates with PA, but this
cannot be explained solely by increased platelet bound VWF following apheresis.
Therefore, additional stressors are probably responsible for the increases observed
in platelet degranulation and storage lesion in products with PA.
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Introduction
Apheresis has specific advantages and disadvantages
compared to other modalities of platelet concentrate pro-
duction [1]. One practical problem in apheresis is the
presence of platelet aggregates in the final product [2, 3].
These structures are poorly defined but manifest as
macroscopic hyaline structures that are clearly visible to
the naked eye, with or without backlighting. Most aggre-
gates that reside in the collected product immediately
after donation, spontaneously dissipate during a resting
phase or following storage under standard blood banking
conditions. However, in certain cases a significant num-
ber of aggregates will persist throughout storage and are
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designated ‘persistent aggregates’ (PA) (Fig. S1). Platelet
concentrates prepared by the buffy coat method do not
contain PA in the final storage bag in our experience. It
is however not clear whether the leukofiltration step dur-
ing component processing is successfully filtering out
aggregates or whether these are simply absent to begin
with. Therefore, this study focuses on PA in apheresis
concentrates.
The advent of PA is unpredictable and yet a relatively
common phenomenon, with roughly 4% of apheresis
products being positive according to the internal scoring
guideline used in our Blood Service [2, 4]. Depending on
the institution’s directives [2], products with PA may be
distributed for transfusion, quarantined until free of
aggregates or immediately destroyed. There are no clini-
cal studies investigating these products, and the aetiology
of PA in apheresis concentrates is not known [3].
During extracorporeal circulation in the apheresis
machine, live endothelium is absent. Endothelial cells
nonetheless provide crucial negative feedback signals to
prevent spontaneous platelet activation in vivo [5]. In
addition, the extracorporeal circulation involves centrifug-
ing and pumping around blood (components) which cause
hydrodynamic shear forces. Here, we hypothesize that PA
formation can be explained by extracorporeal shear force
and the loss of endothelial pacification which, respec-
tively, favour primary VWF–platelet interactions and cel-
lular activation. To address this, VWF and GPIba
molecular interactions were investigated in apheresis pla-
telet concentrates with PA compared to aggregate-free
(AF) controls. Effects on platelet quality during storage
were studied in a model of increased VWF–GPIba binding.
Materials and methods
Study design
Apheresis donations were by voluntary non-remunerated
donors having given informed consent for the use of their
donation for scientific purposes. Approval of an external
ethics review commission was obtained under registration
number B30020142040. Platelet collection from single
donors was on a TRIMA ACCEL (Terumo BCT, Lakewood, CO,
USA) apheresis machine (software version 6.0.6). Standard
operating procedures established at the Belgian Red Cross-
Flanders Blood Service were followed. Collection targets
are depending on prespecified donor parameters including
haematocrit, whole blood platelet count, sex, body weight
and length. Based on these parameters, an optimal target
is proposed by the apheresis machine software. In all
cases, there was dual component donation of plasma and
platelets. The inlet to anticoagulant (acid citric dextrose)
ratio was 11:1 in all cases. Following donation, the plate-
let bag was ‘rested’ label down, without flatbed agitation
for at least 1 h at room temperature. Platelet concentrates
were always supplemented with platelet additive solution
(SSP+, Macopharma, Tourcoing, France).
Persistent aggregates are defined as free-floating pre-
cipitating hyaline particles, noticeable to the naked eye
either during product processing or storage. The Belgian
Red Cross-Flanders Blood Service routinely assesses plate-
let apheresis concentrates for the presence of aggregates
using an in-house arbitrary scoring system reported pre-
viously [2]. In this study, platelets or supernatants of con-
centrates with PA were compared to unpaired AF
products, that is the control group based on the scoring
system (n ≥ 6). Biochemical assays described below were
performed on day one or six postdonation as indicated.
All platelet assays were designed for the study of single
platelets, the visible aggregates were not included.
Flow cytometry
Expression of glycoprotein Iba (GPIba) (anti-
CD42b~fluorescein; Life technologies, Carlsbad, CA, USA)
and P-selectin (anti-CD62P~phycoerythrin; BD Bio-
sciences, Erembodegem, Belgium) was determined using
an acoustic focusing Attune flow cytometer (Life Tech-
nologies). Instrument stability and performance was con-
trolled prior to every experiment using calibrated
fluorescently labelled beads of different scatter properties.
Binding of VWF to platelets was determined using in-
house Alexa Fluor 488 labelled (A20181 from Life Tech-
nologies) polyclonal anti-VWF antibody (Dako, Glostrup,
Denmark). Platelets were incubated with labelled antibod-
ies for 10 min at room temperature in 10 mM 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer,
pH 74 with 09% NaCl (HBS), supplemented with 1 mM
MgSO4 according to Goodall et al. [6]. Phosphatidylserine
exposure was measured using PerCP-Cy5.5 labelled
Annexin V in buffers containing 2 mM CaCl2. As a nega-
tive control for this experiment, calcium was left out.
Median fluorescence intensities were determined of 10 000
cells in the platelet gate which were selected by positive
staining for CD61 (anti-CD61~allophycocyanin; Life Tech-
nologies) and forward scatter. The signals of the negative
isotype antibody controls were used to set threshold gates
including 05% of 10 000 negative events.
Platelet adhesion during blood perfusion in
microfluidic conditions
Reconstituted blood was prepared using platelets from AF
or PA concentrates combined with fresh red blood cells
(RBC) and plasma from an ABO-matched peripheral blood
sample taken from healthy non-medicated volunteers in
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heparin vacutainers (REF368480; BD Diagnostics, Frank-
lin Lakes, NJ, USA). Measures for preserving platelet qui-
escence during phlebotomy were taken into account as
published elsewhere [7]. The blood was centrifuged at
250 g to prepare platelet rich plasma (PRP) and packed
RBC. The PRP and buffy coat were transferred to a new
tube and centrifuged at 4500 g to yield platelet-poor
plasma. This cell pellet was discarded. To reconstitute
blood, the packed RBC and plasma from this fresh blood
were mixed with platelets from AF and PA concentrates
aiming at 40 per cent haematocrit and 250 000 platelets/
ll as described [8].
Perfusion experiments were performed using Vena8
Fluoro+TM biochips (Cellix Ltd, Dublin, Ireland). The
microfluidic channels were incubated with 5 IU/ml VWF
(Wilfactin, CAF-DCF, Brussels, Belgium) at 4°C over-
night and next blocked with HBS containing 10% (w/v)
bovine albumin and 01% (w/v) D-glucose at room tem-
perature for 30 min. Blocking buffer and remainder coat-
ing solution were rinsed with 1 ml HBS buffer. The
reconstituted blood was labelled with calcein-AM (5 lM
final) (Life technologies). Perfusion was performed at
135 dynes/cm2 (3000/s flow rate) using a Mirus Evo
microfluidic pump (Cellix Ltd). Because the Wilfactin
fractionated VWF component contains trace fibrinogen,
50 ng/ml of tirofiban (aggrastat; Sigma-Aldrich, St
Louis, MO, USA) was added to all samples to inhibit inte-
grin aIIbb3 interactions and focus on the VWF–GPIba
interaction. Every 6 s, three side-by-side images were
snapped in real time in each lane during 5 min using an
inverted fluorescent microscope at 1009 magnification
equipped with a Colibri-LED fluorescent light source
(488 nm) and high-resolution CCD camera (all Carl Zeiss,
Oberkochen, Germany). One single image per time-point
was generated by digitally stitching the three side-by-side
images (ZEN2012 software (Carl Zeiss)). Surface coverage
was determined by measuring the fraction of pixels posi-
tive for platelet deposition defined as having a fluores-
cence of 400 arbitrary units or higher. As expected this
parameter was almost immediately steady state in func-
tion of time, because there is no thrombus build-up when
only interactions with VWF are formed [9]. All image
acquisition and analysis variables, including CCD camera
exposure time, LED intensity, binning settings and thresh-
old values, were kept constant throughout this study.
Immunosorbent assays
The platelet cytokines transforming growth factor beta
(TGFb1), chemokine (C-C motif) ligand 5 (CCL5 or
RANTES) and platelet factor 4 (PF4 or CXCL4) were deter-
mined by commercial immunosorbent assays (ELISA) fol-
lowing the instructions of the provider (R&D Systems,
Minneapolis, MN, USA). These assays were based on the
sandwich principle and included validated calibration
standards provided by the manufacturer.
VWF antigen (VWF:Ag) was measured as described
[10]. Binding of VWF to human type III collagen (Sigma-
Aldrich) was measured by ELISA according to the method
described by Siekmann [11]. The level of activated VWF
was determined by ELISA using a nanobody (kind gift
from Dr. P.J. Lenting, Paris, France) specifically binding
to the activated conformation of VWF [12]. To correct for
variation caused by VWF:Ag, equal VWF concentrations
were used for all samples in the assay. D-dimer (Ray-
biotech, Norcross, GA, USA) and fibrinogen (Molecular
Innovations Inc, Novi, MI, USA) concentrations were
determined using commercially available ELISA kits. Total
protein concentration was measured by bicinchoninic acid
assay (Thermo Fisher Scientific, Waltham, MA, USA).
Model of premature VWF–GPIba interaction
Platelet concentrates (n = 5) were prepared by pooling of
six buffy coats, and storage in SSP+ was used for mimick-
ing the effect of premature VWF–GPIba interactions. Each
single product was split in two equal volume daughter
products. One was supplemented with 600 lg/ml of filter-
sterilized ristocetin (in SSP+) and the other with only
vehicle to serve as a paired control. Analysis of platelet
concentrate quality in function of storage was on days 1,
2, 5 and 7 using small volume samples taken through a
sterile connection and a syringe under a safety cabinet.
Quality was assessed by the above described techniques.
All products were assessed for bacterial contamination by
inoculation of a 100 ll sample on agar plates on day 7
and incubation for 24 h at 37°C. None was infected.
Statistical analysis
Comparison of means of laboratory data was with t-test
or Mann–Whitney testing for parametric or nonparamet-
ric datasets, respectively. A significance level of 005 was
used to claim statistical difference. Analyses were per-
formed with PRISM software version 6.01 (GraphPad Soft-
ware Inc, La Jolla, CA, USA). P-values are indicated on
top of the panels, except when non-significant. Data are
shown as mean with standard deviation or median with
interquartile range for parametric or nonparametric data-
sets, respectively. Gaussian distribution was tested using
the Shapiro–Wilk normality test.
Results
Platelets in PA concentrates (n = 11) had significantly
more bound VWF (P = 0009) compared to AF (n = 8)
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(Fig. 1). This was not caused by increased VWF antigen
levels in PA (n = 13) vs. AF (n = 7), on day 1 nor day 6
(Fig. 2a). VWF function is however not solely dependent
on its concentration, and therefore, the level of activated
VWF was measured (Fig. 2b), but no difference could be
found. Notably, significantly lower amounts of activated
VWF were found in all apheresis concentrates when com-
pared to normal human pooled plasma (NHP, dotted hori-
zontal line). VWF collagen binding and GPIba expression
levels were measured (Fig. S2) as well as total protein
concentration, fibrinogen concentration and D-dimer con-
centration, but none of these parameters differed between
study arms (Fig. S3).
Platelet adhesion to immobilized VWF under flow was
neither different between PA (n = 7) and AF (n = 6) in day
1 samples but on day 6, significantly less (P = 0009) VWF
adhesion was seen in PA samples compared to AF controls
(Fig. 3). Platelet counts of the reconstituted samples could
not account for this as these were not significantly differ-
ent (247 – 11 for AF and 266 – 18 for PA, P = NS).
P-selectin expression (P = 0030) as well as cytokine
concentrations (P ≤ 0042) were increased on day 1 in PA
samples (n = 13) compared to AF (n = 7) demonstrating
degranulation early on in the process of collection, pro-
cessing or storage of concentrates with PA (Fig. 4). Plate-
let concentrations in both arms were not significantly
different, and therefore, cytokine concentration increase
was specific.
To model the effects of VWF binding to platelets, risto-
cetin was added to platelet concentrates immediately after
production and storage lesion parameters were measured
in function of time. The model shows that binding of
VWF to platelets on day 1 is increased compared to vehi-
cle-treated controls (Fig. 5). The VWF-binding levels were
similar to those found in apheresis products with PA
(Fig. 1). During storage however VWF binding reversed,
unlike the observation in PA concentrates. Of note, stor-
age lesion parameters in function of storage time were
not increased compared to vehicle-treated controls as
measured by degranulation (Fig. 5b and Fig. S4), GPIba
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Fig. 1 Comparison of VWF binding to platelets
in concentrates with PA compared to AF
controls. (a) Flow cytometry histograms
depicting 10 000 CD61 positive events taken
from a representative AF (black) and PA
concentrate (grey). (b) Median ﬂuorescence
intensities (MFI) of the anti-VWF signal were
collected in AF (n = 8) and PA (n = 11)
concentrates on day 1.
Fig. 2 VWF antigen and activated VWF in supernatants of concentrates with PA and AF controls. (a) VWF antigen (VWF:Ag) concentration was deter-
mined on day 1 (open bars, AF n = 7 and PA n = 13) and day 6 (shaded bars, AF and PA n = 13) postdonation. Concentrations were determined relative
to that in NHP. (b) The levels of activated VWF were determined on day 1 using NHP as a standard arbitrarily set to 100% and indicated by the dotted
horizontal line (AF n = 7 and PA n = 13). In both panels, median and interquartile range are depicted. Differences between groups were not statistically
signiﬁcant for both parameters tested.
© 2015 The Authors
ISBT Science Series published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
Vox Sanguinis (2015)
4 H. B. Feys et al.
expression (Fig. 5c), phosphatidylserine exposure (Fig. 5d)
nor platelet metabolism (Fig. S5).
Discussion
In this study, we demonstrate that platelets in PA concen-
trates had increased degranulation as well as increased
binding of VWF compared to AF controls. Adhesion to
immobilized VWF was decreased in PA products, but only
on day 6 pointing to increased storage lesion. A model of
chemically induced VWF binding was used to mimic
increased VWF–platelet binding but could not show
increases in platelet degranulation nor storage lesion.
The primary interaction between platelets and the dam-
aged vessel wall is highly dependent on the prevailing
fluid shear forces [9] and strengthens in proportion to the
impacting drag [13]. Apheresis involves fluid aspiration
and centrifugation of blood or its components, and this
process equally evokes fluid shear and drag forces [3] that
may facilitate platelet–platelet binding through GPIba
and sheared soluble plasma VWF [14]. Furthermore, our
previous work on this topic indicated that certain donors
Fig. 3 Platelet adhesion to VWF of platelets
from concentrates with PA and AF controls. (a)
Representative snapshots taken at 294 s of
perfusion depicting adhering ﬂuorescently
labelled platelets on day 1 (top panel) and day
6 (bottom panel). Scale bar indicates 100 lm.
(b) Platelet adhesion at 294 s of perfusion (%
SC t294s) is shown as mean surface coverage
with SD. Results are shown for unpaired AF
(n = 6) and PA (n = 7) concentrates on day 1
(open bars) and day 6 (shaded bars).
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Fig. 4 Levels of degranulation in platelets from
concentrates with PA and AF controls. (a)
Median ﬂuorescence intensities (MFI) indicate
the median level of platelet degranulation
using an anti-P-selectin antibody binding to
10 000 CD61 positive events in AF and PA
concentrates. (b–d) The concentration of
platelet related cyto- and chemokines was
determined by immunosorbent assays in the
supernatants of AF and PA concentrates. (b)
TGFb1 in ng/ml, (c) CCL5 in ng/ml and (d)
CXCL4 in lg/ml. All measurements were done
on material from day 1 postdonation. All data
are shown as mean and SD except for TGFb1 in
panel B depicting median and interquartile
range.
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are more likely to routinely donate concentrates with PA
[4]. In that study, we also showed that platelets from PA
products are more sensitive to low-dose ristocetin. Both
VWF and GPIba are polymorphic molecules explaining
biological variation in the quality and number of estab-
lished interactions [15, 16]. Together, this supported the
hypothesis that VWF–GPIba interactions are established
during apheresis and that these may form the basis for
PA formation in a subset of donors.
The current study demonstrates that platelets in con-
centrates with PA indeed carry more bound VWF than AF
controls which is in support of the hypothesis. Increased
VWF binding is clinically relevant to transfusion medi-
cine because it increases macrophage uptake of affected
platelets and subsequent clearance from circulation [17,
18], potentially decreasing transfusion yields. Mutations
in VWF or GPIba can also cause increased binding in rare
diseases like von Willebrand’s disease type 2B and plate-
let-type von Willebrand’s disease, respectively, each with
varying degrees of thrombocytopenia and bleeding [19].
Additional research is needed to demonstrate whether
transfusion of apheresis concentrates with PA or with
higher VWF–platelet binding in general, results in lower
count increments than with AF products.
Binding of VWF to platelets in healthy donors may
show degrees of variation as a consequence of acquired
or hereditary differences in either binding partners [20,
21]. We therefore assessed several VWF laboratory
parameters as well as the GPIba receptor expression levels
in the AF and PA donor population. VWF antigen, colla-
gen binding and activated VWF were not significantly
different, indicating no measurable phenotypic variation
explaining the difference between AF and PA on the basis
of VWF. Of note, VWF:Ag levels rise in both conditions
during storage, as platelets gradually release alpha-gran-
ules.
Moreover, we found no significant difference in GPIba
receptor expression levels, indicating that the number of
receptors is not responsible for the observed increased
VWF binding. However, this does not rule out the possi-
bility of functional GPIba differences between donors that
could account for the observation. Functional GPIba dif-
ferences were not assessed in this study but may be
related to GPIba linkage with the cytoskeleton [22], to its
affinity for VWF [23, 24] or to the signal transduction
cascade that is linked with the GPIb-IX-V complex [25].
Finally, no differences in total protein concentration, fib-
rinogen levels nor D-dimer concentrations were found.
The latter two are important because variable anticoagu-
lation may variably induce thrombin formation which in
turn can affect GPIb-IX-V complexes on platelets. Our
data indicate that on the D-dimer level, there was no
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Fig. 5 Experimental model of increased VWF
binding. (a) The amount of bound VWF, (b)
degranulation, (c) GPIba receptor expression
and (d) apoptosis and/or activation. Median
ﬂuorescence intensities (MFI) are expressed as
median and interquartile range (n = 5) for
samples having been treated with 600 lg/ml
ristocetin on day 1 to model increased VWF–
GPIba binding (●) vs. paired vehicle-treated
control platelets (○, dashed line).
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measurable coagulation contributing to the phenomenon
of PA formation compared to AF concentrates. This sup-
ports the finding that mere increases in the anticoagulant
to plasma ratio has not eliminated the problem of PA in
apheresis collection [26].
Because normal interaction with immobilized VWF
may be compromised when platelets are ‘coated’ with
VWF [27], platelet adhesion was analysed in flow cham-
bers. We found no difference between AF and PA concen-
trates on day 1 indicating that adhesion of platelets from
PA concentrates is normal in the early stages of storage.
However, on day 6, platelets from PA concentrates were
significantly less adhesive than AF indicating accelerated
storage lesion. This corresponds to our previous work
showing increased levels of P-selectin and lactic acid
resulting in lower pH values following storage of PA con-
centrates [4]. Importantly, degranulation is not a conse-
quence of storage itself because platelets have
degranulated early on following apheresis on day 1. This
allows speculation that established VWF–GPIba interac-
tions are required to stimulate platelets to release its
granule content contributing to accelerated storage lesion.
To confirm or refute this hypothesis, we simulated
increases of VWF–GPIba binding in platelet concentrates
prepared from buffy coats by adding low-dose ristocetin
[28] early on in storage (day 1). Immediately after risto-
cetin supplementation, VWF binding increased signifi-
cantly to levels comparable to those in concentrates with
PA. In addition, macroscopic disseminated aggregates
were formed instantaneously which visually resembled
the characteristic transient aggregates collected during
apheresis, but these disappeared within 10 min of storage
on the orbital shaker. In line with this, the laboratory
model of increased VWF–GPIba binding did not result in
increased storage lesion displaying normal metabolism,
degranulation and phosphatidylserine exposure through-
out storage compared with paired vehicle controls. It
could be that molecular differences between the primary
products, that is apheresis vs. buffy coat derived prevent
exact mimicking of PA formation.
Yet, our data collectively indicate that PA formation is
multifactorial, hence not dependent on initial VWF–
GPIba binding alone. Studies on signal transduction from
GPIb-IX-V indeed demonstrate that binding to this partic-
ular receptor does potentiate signals from other receptors
[29–32], but on itself is not sufficient to fully and irre-
versibly activate platelets. Because degranulation is
nonetheless apparent on day 1 already, it is likely that
the observed increase in VWF–GPIba binding has potenti-
ated other signals that have activated platelets during
apheresis from certain donors and thereby causing PA.
In conclusion, this study demonstrates that products
with PA have accelerated storage lesion. This coincides
with increased VWF–platelet binding and platelet degran-
ulation. The former phenomenon can be mimicked (tran-
siently) by the addition of ristocetin while the latter
cannot. Therefore, increased VWF binding to platelets is
not sufficient to explain increased storage lesion. Yet to
be identified additional stressors are probably required to
boost platelet degranulation in products with increased
VWF–GPIba interactions. These are pivotal in speeding
up storage lesion, and future research should indicate if
this influences count increments and haemostasis quality
of stored PA products.
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Additional Supporting Information may be found in the online version of this article:
Fig. S1 Persistent aggregates in apheresis platelet concentrates.
Fig. S2 VWF binding to collagen and the expression of the collagen binding receptor GPIba.
Fig. S3 Total protein and fibrinogen.
Fig. S4 cytokine concentrations in a model for increased VWF binding.
Fig. S5 Metabolism is normal in a model of storage lesion in platelet concentrates with increased VWF-platelet binding.
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